Questões de Concurso
Comentadas sobre palavras conectivas | connective words em inglês
Foram encontradas 232 questões
“________ it rains, we’ll go for a picnic by the river tomorrow”
Choose the CORRECT answer.
The hard cell
Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion market.
Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ...62... methods are morally wrong. They are ...63... a form of abortion or an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.
Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.
The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
The hard cell
Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.
By Stephan Herrera
February 13, 2003
New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion market.
Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ...62... methods are morally wrong. They are ...63... a form of abortion or an activity that could eventually lead to human cloning.
Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.
Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.
Sweden, say analysts, is now in the best position to
capture a worldwide market for drugs based on stem cell
therapies that could grow to $25 billion in the next three to five
years − nearly equal to the whole biotech industry at present.
This estimate doesn't even address the market for stem cells
capable of repairing damaged vital organs like the brain, heart,
and kidneys. If the United States offers an object lesson of what
can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup,
NeuroNova, offer the opposite example. How odd that the
United States, which for generations has been the envy of the
world for its progressive views of science and commercialization,
should now have a biomedical climate chillier than a Swedish
winter.
One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.
Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)
Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.
The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.
If NeuroNova is the first to develop a drug capable of
treating one of several central nervous system disorders − by far
the most lucrative after heart disease products − it will have
done so not because it raised more money or got more media
buzz than the rest. It will have succeeded because the science
is solid, and academe, government, and the investment
community are supportive. Meanwhile, the United States will
look on with envy and wonder how it, a country known for its
entrepreneurial innovation, ever got so short-sighted.
(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)
Text III
Alice Walker (born February 9, 1944), an American novelist, short story writer, poet,
and social activist (https://en.wikipedia.org/wiki/Alice_Walker)
We Alone
We alone can devalue gold
by not caring
if it falls or rises
in the marketplace.
Wherever there is gold
there is a chain, you know,
and if your chain
is gold
so much the worse
for you.
Feathers, shells
and sea-shaped stones
are all as rare.
This could be our revolution:
to love what is plentiful
as much as
what's scarce.
From: https://www.poetrysoup.com/famous/poem/we_alone_23191
Considere a tirinha abaixo.
A palavra ou expressão que conclui adequadamente, na lacuna I, a fala do anjo para Deus é
However, we need to think about animals, too ‘…but is now under threat from nature itself.’ ‘Due to exhaustion or stormy weather…’ ‘As a result of all these factors…’
We can infer that the words in bold:
1. They are called discourse markers or linking words, as they help the speaker to manage the conversation and mark when it changes.
2. Discourse markers are words and phrases used in reading to ‘signpost’ discourse.
3. Linking words show us turns, join ideas together, and generally control communication.
4. Discourse markers are referred to more commonly as ‘linking words’ and ‘linking phrases’, or ‘sentence connectors’.
5. They are used more frequently in speech, unless the speech is very formal.
Choose the alternative which contains all the correct affirmatives.
Choose the alternative that contains the correct ones to complete the sentences.
1. The words in bold, in the text, are, pronouns.
2. The underlined word in: ‘Part of reality television’s appeal is due to its ability to place….’, can be replaced by the word ‘because’ without changing its meaning.
3. In the following sentence: “Although the genre has existed in some form or another since the early years of television…” the words in bold, are being used to express a past action.
4. The negative form of the following sentence: ‘Although the genre has existed in some form or another since the early years of television…’, is Although the genre doesn’t have existed in some form or another since the early years of television…’.
Choose the alternative which contains the correct affirmative.
They propose the mixing of __________________and _______________comprehension with __________________and ________________ expression.
Choose the alternative that contains the correct words to complete the sentence.
On the basis of this definition, it is correct to say that the words “almost” (last sentence of the second paragraph), “favor” (third sentence of the fourth paragraph), “which” (first sentence of the last paragraph) and “between” (third sentence of the last paragraph), which were taken from text 4A1-II, are, respectively,
[…] If a teacher is normally noisy and energetic as a teacher, he or she should spend a class behaving more calmly. This is so because each time teachers break their own behavior patterns, they send a ripple through the class. That ripple is a mixture of surprise and curiosity and it is a perfect starting point for student involvement. The need for surprise and curiosity within a fifty-minute lesson is also overwhelming. This can be seen most clearly with children at primary and secondary levels, but even adults need a varied diet to keep them stimulated. However, variety is not the same as anarchy, since students need a certain amount of predictability for the sake of stability.
(Adapted from: HARMER, Jeremy. How to be
a good teacher. England: Longman, 1998, p. 5.)
Ainda no trecho acima o uso do conectivo since indica:
Read the following text and answer question.
Introduction to global food loss and food waste
Food losses and food waste are quickly becoming a top global issue, because while there are millions of families with children starving, others are living in abundance, with many others carelessly throwing food away. Many of us have wasted food in one way or the other, but the real food losses and waste matter is ______ than just consumer food waste.
From farming fields and storage places, through transportation, processing, market places, down to
consumption places such as homes, schools, restaurants and workplaces, more than half of all food
produced globally go to waste. This is a tragedy!
In developing countries, it takes a lot of man-power to produce food. In more advanced countries, machines and technology are used, but the drain on energy, destruction of vegetative lands, the use of chemicals and ______ impact on the environment are phenomenal. Putting all that together, it is clear that a major problem has emerged and we are all in a position to help in one way or the other.
(Adapted from: https://goo.gl/ySEn3F. Access: 01/23/2018)
The words such as in “ such as homes, schools, restaurants and workplaces…” indicates
Read text I and answer the question that follow it.
Text I
The New Rules of Data Privacy
The data harvested from our personal devices, along with our trail of electronic transactions and data from other sources, now provides the foundation for some of the world’s largest companies. […] For the past two decades, the commercial use of personal data has grown in wild-west fashion. But now, because of consumer mistrust, government actions, and competition for customers, those days are quickly coming to an end.
For most of its existence, the data economy was structured around a “digital curtain” designed to obscure the industry’s practices from lawmakers and the public. Data was considered company property and a proprietary secret, even though the data originated from customers’ private behavior. That curtain has since been lifted and a convergence of consumer, government, and market forces are now giving users more control over the data they generate. Instead of serving as a resource that can be freely harvested, countries in every region of the world have begun to treat personal data as an asset owned by individuals and held in trust by firms.
This will be a far better organizing principle for the data economy. Giving individuals more control has the potential to curtail the sector’s worst excesses while generating a new wave of customer-driven innovation, as customers begin to express what sort of personalization and opportunity they want their data to enable. And while Adtech firms in particular will be hardest hit, any firm with substantial troves of customer data will have to make sweeping changes to its practices, particularly large firms such as financial institutions, healthcare firms, utilities, and major manufacturers and retailers.
Leading firms are already adapting to the new reality as it unfolds. The key to this transition — based upon our research on data and trust, and our experience working on this issue with a wide variety of firms— is for companies to reorganize their data operations around the new fundamental rules of consent, insight, and flow.
[…]
Federal lawmakers are moving to curtail the power of big tech. Meanwhile, in 2021 state legislatures proposed or passed at least 27 online privacy bills regulating data markets and protecting personal digital rights. Lawmakers from California to China are implementing legislation that mirrors Europe’s GDPR, while the EU itself has turned its attention to regulating the use of AI. Where once companies were always ahead of regulators, now they struggle to keep up with compliance requirements across multiple jurisdictions.
Adapted from: https://hbr.org/2022/02/the-new-rules-of-data-privacy
February 25, 2022 – Retrieved September 6, 2022
The term “However” (line 10) can be correctly replaced by the conjunction Hence, without changing its meaning.